Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Progression of Occlusive Atherosclerosis: Long-Term Administration of Pyridinol Carbamate

Progression of Occlusive Atherosclerosis: Long-Term Administration of Pyridinol Carbamate Abstract The effects of pyridinol carbamate, a drug with demonstrated capacity to inhibit development of atherosclerotic plaques in the rabbit, were studied in humans with symptoms of arterial occlusive disease in the lower extremities. Microcirculation, perfusion, claudication distance, peripheral pulsations, and angiographic appearances were supplemented by clinical impressions over a two-year period. Although the drug was discontinued in several patients from a larger group because of gastrointestinal tract symptoms, and for other reasons, seven of eight patients receiving it showed no progression of their disease, whereas all 15 patients receiving identical-appearing placebos did. Although the number of patients is not sufficient to warrant statistical conclusions, the observations were totally objective and strongly encourage further control studies. References 1. Redisch W, Kuthan F, Camerini-Davalos R, et al: Vascular disease in diabetics: I. Incidence . Vasa 2:40-44, 1973. 2. Gessner FB: Hemodynamic theories of atherogenesis . Circ Res 33:259-266, 1973.Crossref 3. Kuthan F, Burkhalter A, Baitsch R, et al: Development of occlusive arterial disease in lower limbs . Arch Surg 103:545-547, 1971.Crossref 4. Warren R, Gomez RL, Marston JAP, et al: Femoropopliteal arteriosclerosis obliterans: Arteriographic patterns and rates of progression . Surgery 55:135-143, 1964. 5. Shimamoto T, Sunga T: The contraction and blebbing of endothelial cells accompanies by acute infiltration of plasma substances into the vessel wall and their prevention , in Shimamoto T, Numano F (eds): Atherogenesis II . Amsterdam, Excerpta Medica, 1973, pp 3-31. 6. Redisch W, Terry EN, Rouen LR, et al: A study of the efficacy and safety of pyridinol carbamate in patients with demonstrable occlusive arterial disease , in Shimamoto T, Numano F (eds): Atherogenesis II . Amsterdam, Excerpta Medica, 1973, pp 287-294. 7. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal . Nature 194:927-929, 1962.Crossref 8. Hellem AJ: The adhesiveness of human blood platelets in vitro . Scand J Clin Lab Invest 12( (suppl 51) ):1-117, 1960.Crossref 9. Strandness DE Jr: Peripheral Arterial Disease: A Physiologic Approach . Boston, Little Brown & Co, 1969, p 124. 10. Clauss RH, Redisch W: Remediable Arterial Disease . New York, Grune & Stratton Inc, 1971, pp 31-33. 11. Alpert JS, Coffman JD, Balodimos MC, et al: Capillary permeability and blood flow in skeletal muscle of patients with diabetes mellitus and genetic prediabetes . N Engl J Med 286:454-460, 1972.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Progression of Occlusive Atherosclerosis: Long-Term Administration of Pyridinol Carbamate

Loading next page...
 
/lp/american-medical-association/progression-of-occlusive-atherosclerosis-long-term-administration-of-iQQfgUZ9bk
Publisher
American Medical Association
Copyright
Copyright © 1975 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1975.01360090028006
Publisher site
See Article on Publisher Site

Abstract

Abstract The effects of pyridinol carbamate, a drug with demonstrated capacity to inhibit development of atherosclerotic plaques in the rabbit, were studied in humans with symptoms of arterial occlusive disease in the lower extremities. Microcirculation, perfusion, claudication distance, peripheral pulsations, and angiographic appearances were supplemented by clinical impressions over a two-year period. Although the drug was discontinued in several patients from a larger group because of gastrointestinal tract symptoms, and for other reasons, seven of eight patients receiving it showed no progression of their disease, whereas all 15 patients receiving identical-appearing placebos did. Although the number of patients is not sufficient to warrant statistical conclusions, the observations were totally objective and strongly encourage further control studies. References 1. Redisch W, Kuthan F, Camerini-Davalos R, et al: Vascular disease in diabetics: I. Incidence . Vasa 2:40-44, 1973. 2. Gessner FB: Hemodynamic theories of atherogenesis . Circ Res 33:259-266, 1973.Crossref 3. Kuthan F, Burkhalter A, Baitsch R, et al: Development of occlusive arterial disease in lower limbs . Arch Surg 103:545-547, 1971.Crossref 4. Warren R, Gomez RL, Marston JAP, et al: Femoropopliteal arteriosclerosis obliterans: Arteriographic patterns and rates of progression . Surgery 55:135-143, 1964. 5. Shimamoto T, Sunga T: The contraction and blebbing of endothelial cells accompanies by acute infiltration of plasma substances into the vessel wall and their prevention , in Shimamoto T, Numano F (eds): Atherogenesis II . Amsterdam, Excerpta Medica, 1973, pp 3-31. 6. Redisch W, Terry EN, Rouen LR, et al: A study of the efficacy and safety of pyridinol carbamate in patients with demonstrable occlusive arterial disease , in Shimamoto T, Numano F (eds): Atherogenesis II . Amsterdam, Excerpta Medica, 1973, pp 287-294. 7. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal . Nature 194:927-929, 1962.Crossref 8. Hellem AJ: The adhesiveness of human blood platelets in vitro . Scand J Clin Lab Invest 12( (suppl 51) ):1-117, 1960.Crossref 9. Strandness DE Jr: Peripheral Arterial Disease: A Physiologic Approach . Boston, Little Brown & Co, 1969, p 124. 10. Clauss RH, Redisch W: Remediable Arterial Disease . New York, Grune & Stratton Inc, 1971, pp 31-33. 11. Alpert JS, Coffman JD, Balodimos MC, et al: Capillary permeability and blood flow in skeletal muscle of patients with diabetes mellitus and genetic prediabetes . N Engl J Med 286:454-460, 1972.Crossref

Journal

Archives of SurgeryAmerican Medical Association

Published: Mar 1, 1975

References